Antispasmodic (antimuscarinic)
Relief of pain and cramps of the gastrointestinal tract (stomach and intestines), biliary tract and urinary tract associated with smooth-muscle spasm, e.g. in irritable bowel syndrome.
Also known as: Buscopan, butilbrometo de escopolamina, hyoscine butylbromide, butylscopolamine
Buscopan SmPC (EMC-UK, product 1775).
Buscopan SmPC (EMC-UK, product 1775).
No documented drug–drug interactions for this medicine.
Hyoscine butylbromide should be taken before meals to optimise the antispasmodic effect.
Take 30 minutes before meals.
EMC-UK (MHRA) — approved Hyoscine butylbromide SmPC: https://www.medicines.org.uk/emc/product/1775/smpc
The antimuscarinic effect may worsen urinary retention.
Use with caution in patients with urinary obstruction.
EMC-UK (MHRA) — approved Hyoscine butylbromide SmPC: https://www.medicines.org.uk/emc/product/1775/smpc
The antimuscarinic effect may precipitate an acute angle-closure glaucoma attack.
Do not use in patients with angle-closure glaucoma.
EMC-UK (MHRA) — approved Hyoscine butylbromide SmPC: https://www.medicines.org.uk/emc/product/1775/smpc
Data on hyoscine butylbromide in pregnancy are limited; oral use is accepted when indicated.
Avoid unless necessary, at the lowest effective dose.
Excreted into breast milk in small amounts; probably compatible.
No specific additional contraception.
EMC-UK (MHRA) — approved Hyoscine butylbromide SmPC: https://www.medicines.org.uk/emc/product/1775/smpc
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Anticholinergic (antimuscarinic) that blocks muscarinic receptors of visceral smooth muscle, relieving gastrointestinal, biliary and urinary spasm. As a quaternary ammonium compound it does not cross the blood-brain barrier, so central effects are minimal.
Competitive antagonism of M2/M3 muscarinic receptors of smooth muscle, reducing spasm and associated pain; high polarity limits absorption and central passage.
Highly polar quaternary ammonium compound: oral absorption ~8% and systemic bioavailability < 1%; does not cross the blood-brain barrier.
Partially metabolized; elimination is renal (~50%) and fecal. The spasmolytic effect is predominantly local in the GI tract.
Elimination half-life ~5 h (Buscopan SmPC data).
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
